In
collaboration with the International Mesothelioma Interest Group (IMIG), the
International Association for the Study of Lung Cancer (IASLC) decided to
update the staging system for malignant pleural mesothelioma (MPM) by
developing a large international database.
It is
widely known that an accurate staging system is essential for assessing
the benefit of new MPM therapies. However
until the mid-1990s, no such evidence-based staging systems existed and few
utilized the TNM (tumor, node, metastasis) system which was developed to
achieve consensus on one globally recognized standard for classifying the
extent of the cancer spread by using the size and extension of the primary
tumor, its lymphatic involvement and the presence of metastases to classify the
progression of cancer. Eventually these revisions, including adopting the TNM
system, were incorporated and accepted by the UICC (International Union Against
Cancer) and the AJCC (American Joint Commission on Cancer) as the international
MPM staging system.
This
article succinctly reviews information from analyses of the IASLC database
which is currently the largest multicenter and international database in MPM
and identifies areas in which the current staging system should be revised.
As IASLC
and IMIG investigators continue to expand their database, they expect the data gathered will more accurately
reflect the clinicopathological and treatment-related prognostic factors which
significantly influence overall survival based on the TNM staging system, tumor
histology, gender, age and type of operation.
I would like to say that this blog really convinced me, you give me best information! Thanks, very good post.
ReplyDeletestaging systems